by editor | Oct 22, 2015 | Buzz
Shares of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS) are up as much as 17% in early trading as the Buzz grows on today’s press release regarding AMBS’ orphan drug status application for eltroprazine in the treatment of levodopa-induced dyskinesia...
by GlobeNewsWire | Oct 6, 2015 | Globe Newswire
– Renishaw plc’s convection-enhanced delivery device results in accurate targeting and distribution of MANF to Parkinson’s disease-associated brain areas – – Study confirms the potential of convection-enhanced delivery of MANF as a novel treatment...
by GlobeNewsWire | Oct 1, 2015 | Globe Newswire
Company is Currently Evaluating Human Clinical Data From Previous Studies Supporting Clinical Development Program Expansion Beyond Treatment of Adult Burns Into Pediatric Burns Published Data Support Development Expansion Into Congenital Giant Hairy Nevus SAN...
by GlobeNewsWire | Oct 1, 2015 | Globe Newswire
SAN FRANCISCO and GENEVA, Oct. 1, 2015 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan indications and neurology, announced that it has completed the...
by GlobeNewsWire | Sep 3, 2015 | Globe Newswire
SAN FRANCISCO and GENEVA, Sept. 3, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that at its 2015 Annual...
